HGH Fragment 176-191: The Complete Guide

Overview

Human growth hormone (hGH) is a 191-amino-acid protein produced by the anterior pituitary gland. It plays a critical role in growth, metabolism, and body composition throughout life. Among its many metabolic effects, hGH is a potent lipolytic agent — it promotes the breakdown of stored triglycerides in adipose (fat) tissue. Researchers in the 1990s and 2000s identified that this fat-burning activity was concentrated in a small region near the C-terminal end of the molecule: amino acids 176 through 191.

HGH Fragment 176-191 (often abbreviated as HGH Frag 176-191 or simply "Frag") is a synthetic version of this specific 16-amino-acid sequence. The peptide was developed and characterized primarily by researchers at Monash University in Melbourne, Australia, led by Frank Ng and Gary Borstein. Their work demonstrated that this small fragment retained the lipolytic properties of full-length growth hormone while lacking most of its other biological activities — particularly the growth-promoting, insulin-antagonistic, and IGF-1-stimulating effects (Ng et al., 2000).

This selectivity is what makes HGH Fragment 176-191 distinctive. Full-length growth hormone is a powerful fat-loss agent, but its clinical use for body composition is limited by significant side effects: insulin resistance, fluid retention, carpal tunnel syndrome, joint pain, and the potential to promote growth of organs and tumors via IGF-1 elevation. By isolating just the fat-metabolizing portion of the molecule, researchers aimed to develop a peptide that could reduce adiposity without these systemic complications.

HGH Fragment 176-191 is closely related to AOD-9604 (Anti-Obesity Drug 9604), which is the same 176-191 sequence with a tyrosine residue added at the N-terminus. AOD-9604 was developed as a pharmaceutical candidate and advanced further through clinical trials, though it ultimately failed to gain FDA approval for obesity. The two peptides share similar mechanisms of action, and much of the clinical trial data cited in the context of HGH Fragment research actually derives from AOD-9604 studies (Heffernan et al., 2001).

HGH Fragment 176-191 has no FDA-approved indication. It has not completed the clinical trial process required for regulatory approval. It is available through research chemical suppliers and, in some cases, compounding pharmacies, but it is classified as an experimental research compound. The evidence base, while promising in preclinical models, does not yet meet the standard required for approved therapeutic use.

Quick Facts

HGH Fragment 176-191 vs. AOD-9604 vs. Full HGH

Understanding the differences between these three compounds is essential for anyone researching this class of peptides. The following comparison table summarizes the key distinctions.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

To understand how HGH Fragment 176-191 works, it helps to first understand the lipolytic mechanism of full-length human growth hormone — and then how the fragment isolates just that specific activity.

How Full-Length HGH Burns Fat

Human growth hormone promotes fat loss through several interconnected mechanisms:

• Direct lipolysis: hGH binds to growth hormone receptors (GHR) on adipocytes (fat cells), activating hormone-sensitive lipase (HSL) via the beta-3 adrenergic pathway. HSL catalyzes the hydrolysis of stored triglycerides into free fatty acids and glycerol, releasing them into the bloodstream for use as energy (Ng et al., 2000).
• Anti-lipogenic action: hGH inhibits the activity of lipoprotein lipase (LPL) and acetyl-CoA carboxylase in adipose tissue, reducing the rate at which circulating fatty acids are taken up and stored as new fat (Ng & Borstein, 2003).
• Metabolic rate enhancement: hGH increases basal metabolic rate and shifts substrate utilization toward fat oxidation, meaning the body preferentially burns fat rather than carbohydrates at rest.
• IGF-1 mediation: Many of HGH's growth-promoting and anabolic effects are mediated through insulin-like growth factor 1 (IGF-1), which is produced by the liver in response to GH stimulation. IGF-1 drives cell proliferation, tissue growth, and organ enlargement.

The problem with using full-length HGH purely for fat loss is that you get all of these effects simultaneously — including the IGF-1 elevation, insulin resistance, fluid retention, and growth-promoting effects that are undesirable or dangerous when the only goal is reducing adiposity.

How the Fragment Isolates Lipolysis

The key insight from Ng and Borstein's research at Monash University was that the lipolytic activity of growth hormone could be localized to a specific region of the molecule. Through systematic analysis of growth hormone fragments, they determined that amino acids 176-191 — the C-terminal tail of the protein — retained the ability to stimulate fat breakdown while lacking the structural domains required for:

• GH receptor dimerization — full GHR activation requires binding of the complete GH molecule across two receptor subunits, which a small fragment cannot achieve
• IGF-1 axis stimulation — the fragment does not activate the JAK2-STAT5 signaling cascade that drives hepatic IGF-1 production
• Insulin antagonism — the glucose-disrupting effects of GH involve structural regions outside the 176-191 sequence
• Cell proliferation signaling — the mitogenic (growth-promoting) activity of GH requires the full-length protein

In their 2000 paper published in Obesity Research, Ng and colleagues demonstrated that HGH Fragment 176-191 stimulated lipolysis in both isolated adipocytes (fat cells in a dish) and in obese mice to a degree comparable to full-length hGH, without producing the hyperglycemia (elevated blood sugar) or insulin resistance seen with full hGH treatment (Ng et al., 2000).

The Lipolysis Pathway: Step by Step

Based on the available preclinical research, HGH Fragment 176-191 appears to promote fat loss through the following pathway:

1. Binding to adipocyte membranes: The fragment interacts with cell-surface receptors or membrane components on adipocytes. The exact binding target is not fully characterized — it may involve a partial interaction with the GH receptor or a distinct mechanism. This is an area of ongoing research (Ng & Borstein, 2003).
2. Activation of beta-3 adrenergic signaling: The fragment appears to stimulate the beta-3 adrenergic pathway in fat cells, which is the primary lipolytic signaling cascade. This involves cyclic AMP (cAMP) elevation and protein kinase A (PKA) activation.
3. Hormone-sensitive lipase (HSL) activation: PKA phosphorylates HSL, the key enzyme that catalyzes the breakdown of stored triglycerides into glycerol and free fatty acids.
4. Triglyceride hydrolysis: Activated HSL cleaves triglycerides stored in lipid droplets within adipocytes, releasing free fatty acids (FFAs) and glycerol into the bloodstream.
5. Fatty acid oxidation: Released FFAs are transported to mitochondria in muscle and other tissues, where they undergo beta-oxidation to produce ATP (energy). This is the actual "fat burning" step.
6. Lipogenesis inhibition: Simultaneously, the fragment inhibits the enzymes involved in de novo lipogenesis (new fat storage), reducing the rate at which dietary calories are converted to stored fat (Wu et al., 2003).

Why Fasting State Matters

HGH Fragment 176-191 is typically administered in a fasted state, and this is not arbitrary — it reflects the biochemistry of lipolysis. In the fed state, elevated insulin levels actively suppress lipolysis through activation of phosphodiesterase 3B (PDE3B), which degrades cAMP and inactivates the lipolytic cascade. Even a modest insulin elevation from food intake can blunt or negate the fragment's ability to stimulate fat breakdown.

This is analogous to how endogenous growth hormone's fat-burning effects are most pronounced during overnight fasting: GH is released in pulses during sleep, and its lipolytic activity occurs in the context of low insulin. Administering the fragment in a fasted state recreates this favorable hormonal environment (Ng et al., 2000).

What the Fragment Does NOT Do

Understanding what HGH Fragment 176-191 does not do is as important as understanding what it does. Based on the available research:

• Does NOT increase IGF-1 levels: Multiple studies have confirmed that the fragment does not elevate circulating IGF-1. This is significant because IGF-1 mediates many of full-length HGH's growth-promoting (and potentially harmful) effects, including cell proliferation, organ growth, and tumor promotion (Ng et al., 2000).
• Does NOT affect blood glucose: Unlike full-length HGH, which causes dose-dependent insulin resistance and can significantly raise blood glucose, the fragment has shown no effect on glucose homeostasis in animal studies and limited human data (Heffernan et al., 2001).
• Does NOT promote lean muscle growth: The fragment lacks the anabolic, muscle-building properties of full-length HGH. It is a fat-specific agent, not a general growth agent.
• Does NOT promote bone or organ growth: Without IGF-1 stimulation, the fragment does not carry the risk of acromegaly-like effects (enlarged jaw, hands, feet, internal organs) associated with chronic hGH use.
• Does NOT affect cartilage or connective tissue: The fragment does not stimulate chondrocyte proliferation or collagen synthesis.

Comparison with Full HGH Mechanism

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Uses

FDA Status

HGH Fragment 176-191 has no FDA-approved indication. It is not classified as a drug, dietary supplement, or approved biologic product by the FDA. It has not completed the clinical trial process required for FDA approval. Any clinical use is considered experimental. Its close relative AOD-9604 completed Phase 2b trials for obesity but did not advance to Phase 3 or receive FDA approval.

Primary Investigational Use: Fat Loss and Body Composition

HGH Fragment 176-191 was developed specifically as an anti-obesity agent. Its primary use, both in research and in clinical practice among providers who prescribe it, is targeted fat reduction. The peptide is used by individuals seeking to:

• Reduce overall body fat percentage — particularly stubborn adipose tissue that has not responded to diet and exercise alone
• Improve body composition — reducing fat mass while preserving lean mass (the fragment does not promote muscle growth, but it also does not cause muscle wasting)
• Target visceral fat — some preclinical data suggests preferential mobilization of visceral (abdominal) adipose tissue, though this is not conclusively established in humans (Wu et al., 2003)
• Avoid HGH side effects — individuals who want the fat-loss benefits of growth hormone therapy without the insulin resistance, fluid retention, joint pain, and IGF-1 elevation

Clinical Context: Who Uses It

In clinical practice, HGH Fragment 176-191 is most commonly used by:

Potential Metabolic Applications

Beyond direct fat loss, HGH Fragment 176-191 has been investigated for several related metabolic applications based on preclinical data:

• Lipid profile improvement: Fat mass reduction is generally associated with improvements in cholesterol and triglyceride levels, though no direct lipid-modifying effect of the fragment has been independently confirmed.
• Visceral fat reduction: Visceral adipose tissue (the metabolically dangerous fat surrounding organs) appears to be responsive to lipolytic stimulation by the fragment. Reducing visceral fat is associated with reduced risk of type 2 diabetes, cardiovascular disease, and metabolic syndrome (Wu et al., 2003).
• Cartilage regeneration: AOD-9604, the closely related compound, has been investigated for osteoarthritis and cartilage repair, with some positive preclinical results. However, these effects may be specific to AOD-9604 and not shared by the unmodified fragment (Kwon et al., 2012).

What HGH Fragment 176-191 Is NOT Used For

• Muscle building: The fragment does not promote muscle hypertrophy or increase strength. It is not a replacement for HGH or anabolic agents in muscle-building protocols.
• Anti-aging: Full-length HGH has been marketed (controversially) as an anti-aging therapy due to its effects on skin, bone, and body composition. The fragment lacks these broad anti-aging properties because it does not raise IGF-1 or activate full GH receptor signaling.
• Height increase: The fragment does not promote linear bone growth or cartilage proliferation at growth plates.
• Injury healing: Unlike BPC-157 or TB-500, the fragment does not promote tissue repair, tendon healing, or wound recovery.
• Morbid obesity treatment: As a monotherapy, the fragment is not potent enough for significant weight loss in morbidly obese individuals. It is a body-composition refinement tool, not a primary obesity intervention.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Dosing

Commonly Reported Protocols

Dosing protocols above are extrapolated from published preclinical research and reported clinical practice — not from FDA-approved labeling. Key references: Ng et al., 2000 · Wu et al., 2003 · Heffernan et al., 2001

The Critical Role of Fasting

Unlike many peptides where timing relative to food is a preference, fasting is considered essential for HGH Fragment 176-191 to work effectively. The reason is biochemical:

• Insulin suppresses lipolysis: Even modest insulin elevation from food intake activates phosphodiesterase 3B (PDE3B), which degrades cAMP and directly shuts down the lipolytic cascade the fragment is trying to stimulate.
• Carbohydrates are the worst offender: A carbohydrate-containing meal can raise insulin sufficiently to negate the fragment's fat-burning effect for 2–3 hours.
• Pre-dose fast: Most protocols recommend at least 2 hours without food before injection, with ideally no food for 30–60 minutes after injection.
• Optimal windows: First thing in the morning (after overnight fast) and before bed (at least 2–3 hours after the last meal) are preferred timing windows because insulin is naturally low during these periods.

Administering HGH Fragment 176-191 after a meal — particularly a carbohydrate-rich meal — is widely considered to render the injection largely ineffective. This is the single most important practical consideration for this peptide.

Injection Sites

HGH Fragment 176-191 is administered via subcutaneous injection. Common injection sites include:

• Abdominal area: Most commonly used site. Inject into the subcutaneous fat layer of the abdomen, at least 2 inches from the navel. Rotate injection sites to prevent lipodystrophy (localized fat tissue changes).
• Thigh (anterior/lateral): Alternative site with good subcutaneous tissue access.
• Upper arm (tricep area): Less common but acceptable for subcutaneous injection.

There is no evidence that injecting near a specific body fat deposit results in preferential fat loss from that area. Lipolysis is a systemic process — the fragment enters the bloodstream and acts on adipocytes throughout the body. Injecting into the abdominal area is preferred for convenience and ease of access, not for "spot reduction."

Cycling Patterns

There is no established evidence base for optimal treatment duration or cycling. Commonly reported patterns in clinical practice include:

• Standard cycle: 8–12 weeks on, 4 weeks off, reassess body composition and decide whether to continue
• Extended cycle: 12–16 weeks continuous use, followed by a break of equal duration. Used for more significant fat-loss goals.
• Intermittent use: 5 days on, 2 days off (weekdays on, weekends off). Some practitioners recommend this pattern to prevent receptor desensitization, though there is no strong evidence for this approach.
• Goal-based discontinuation: Use until target body composition is achieved, then discontinue and maintain results through diet and exercise.

Reconstitution and Preparation

HGH Fragment 176-191 is typically supplied as a lyophilized (freeze-dried) powder that requires reconstitution with bacteriostatic water before use. Preparation and injection technique should be demonstrated and supervised by your prescribing healthcare provider or pharmacist.

• Typical vial sizes: 2 mg or 5 mg of lyophilized peptide
• Reconstitute with bacteriostatic water (preserved with 0.9% benzyl alcohol)
• Add water slowly along the vial wall; do not shake — gently swirl or allow to dissolve passively
• Use insulin syringes (29–31 gauge, 0.5 mL or 1 mL) for subcutaneous injection

Storage

• Lyophilized (unreconstituted) powder: Store refrigerated (2–8°C / 36–46°F). Stable for months when kept dry and cold. Can be stored frozen for longer-term storage.
• Reconstituted solution: Refrigerate and use within 3–4 weeks. Do not freeze reconstituted peptide. Discard if solution becomes cloudy or discolored.
• Light sensitivity: Protect from direct light. Some practitioners recommend wrapping reconstituted vials in aluminum foil.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Results: What Research and Users Report

Preclinical Research Data

The strongest evidence for HGH Fragment 176-191's fat-loss effects comes from animal studies conducted by the Monash University group:

Human Clinical Data (AOD-9604)

The most relevant human data comes from clinical trials of AOD-9604, the closely related compound (HGH Fragment 176-191 + N-terminal tyrosine). While not identical to the unmodified fragment, AOD-9604 shares the same core mechanism and is generally considered pharmacologically comparable for fat-loss purposes.

• Phase 2b trial (2004): A randomized, double-blind, placebo-controlled trial of oral AOD-9604 in 300 obese adults showed statistically significant weight loss at the 1 mg/day dose compared to placebo over 12 weeks. The treatment group lost an average of 2.6 kg (5.7 lbs) more than the placebo group. However, the magnitude of weight loss was considered insufficient for regulatory approval as a stand-alone obesity treatment (Ng & Borstein, 2003).
• Safety data: Across clinical trials involving over 900 subjects, AOD-9604 showed a favorable safety profile with no significant adverse events, no effect on IGF-1 levels, no effect on glucose tolerance, and no antibody formation (Stier et al., 2011).
• Oral bioavailability: AOD-9604 was formulated for oral administration in clinical trials. HGH Fragment 176-191 is typically administered by injection, which may provide higher bioavailability and potentially greater efficacy than the oral route used in clinical studies.

Reported User Timeline

Realistic Expectations

Based on the available evidence and user reports, realistic expectations for HGH Fragment 176-191 include:

• Fat loss rate: An additional 0.5–1.5 lbs of fat loss per week beyond what diet and exercise alone would produce. This is a modest but meaningful increment over a multi-week period.
• Total fat loss over a cycle: 4–12 lbs of fat loss over an 8–12 week cycle, depending on starting body composition, caloric deficit, exercise, and individual response.
• Body composition improvement: Because the fragment promotes fat loss without affecting lean mass, the net effect is improved body composition — lower fat percentage, preservation of muscle.
• Not a miracle: The fragment is not a substitute for a caloric deficit. It is an adjunct that may enhance the rate and magnitude of fat loss in the context of a structured diet and exercise program. Users who take the fragment without changing their diet or activity level report minimal results.

Factors Affecting Results

• Fasting compliance: The single most important factor. Users who consistently administer the fragment in a true fasted state report significantly better results than those who are inconsistent with timing.
• Caloric deficit: The fragment enhances fat mobilization, but the body must still be in a caloric deficit to achieve net fat loss. Without a deficit, mobilized fatty acids are simply re-esterified (stored again as fat).
• Exercise: Cardiovascular exercise performed 30–60 minutes after injection may enhance fat oxidation by providing an energy demand for the mobilized fatty acids. Resistance training helps preserve lean mass during the caloric deficit.
• Product quality: Variability between peptide suppliers means that product purity and actual peptide content differ significantly. Poor-quality products may produce no results regardless of protocol adherence.
• Individual variation: Response to any lipolytic agent varies based on genetics, hormonal status, insulin sensitivity, body composition starting point, and other factors.

Limitations of Reported Results

Important caveats when interpreting results:

• Placebo effect: When investing money and effort into a fat-loss protocol, the expectation of results can influence perceived outcomes. Without blinding, this cannot be excluded.
• Concurrent interventions: Most users implement the fragment alongside improved diet and increased exercise. Attributing results specifically to the fragment versus lifestyle changes is impossible without controlled studies.
• Selection bias: Users who experience good results are more likely to report them publicly than those who experienced no benefit.
• No Phase 3 data for the fragment itself: Direct human efficacy data is from AOD-9604, not the unmodified fragment. The two compounds are similar but not identical.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

Reported Side Effects

Note: These rates are based on clinical reports, AOD-9604 clinical trial safety data, and user experience reports — not from large Phase 3 trials of the fragment itself. True incidence rates in humans have not been formally established.

What the Fragment Does NOT Cause (Unlike Full HGH)

One of the primary advantages of HGH Fragment 176-191 over full-length growth hormone is the absence of several common and serious HGH side effects:

AOD-9604 Safety Data (Closest Human Evidence)

The most comprehensive human safety data comes from AOD-9604 clinical trials, which enrolled over 900 subjects across multiple studies. Key findings:

• No serious adverse events were attributed to AOD-9604 across clinical trials (Stier et al., 2011)
• No effect on IGF-1: Serum IGF-1 levels were unchanged from baseline throughout treatment periods
• No effect on glucose tolerance: Oral glucose tolerance tests showed no deterioration during treatment
• No antibody formation: No neutralizing antibodies against the peptide or against endogenous growth hormone were detected
• No dose-limiting toxicity: Even at the highest doses tested, no safety signals emerged that would limit dosing

Theoretical Risks and Concerns

• Unknown long-term effects: The longest human exposure data comes from 12–24 week clinical trials. Chronic use beyond this timeframe has not been studied systematically. Long-term effects on adipose tissue biology, hormonal feedback loops, or other systems are unknown.
• Receptor desensitization: It is theoretically possible that chronic stimulation of the lipolytic pathway could lead to receptor downregulation or desensitization, reducing the fragment's effectiveness over time. This is the rationale behind cycling protocols, though direct evidence for desensitization is limited.
• Hypoglycemia risk in specific populations: While the fragment does not affect blood glucose in healthy or obese individuals, individuals taking insulin or sulfonylureas should be monitored, as enhanced fat oxidation during fasting could theoretically affect glucose dynamics.
• Product contamination: Research-grade peptides may contain impurities, degradation products, or contaminants that could cause adverse effects unrelated to the peptide itself. This is a source-dependent risk, not an inherent property of the molecule.
• Pregnancy and breastfeeding: No safety data exists. Use during pregnancy or breastfeeding should be avoided.

Drug Interactions

No formal drug interaction studies have been conducted with HGH Fragment 176-191. Theoretical interactions include:

• Insulin and oral hypoglycemics: Enhanced fat mobilization during fasting could affect glucose dynamics. Monitor blood glucose more closely.
• Full-length HGH or GH secretagogues: Co-administration with full HGH, ipamorelin, CJC-1295, or other GH-stimulating agents could have additive lipolytic effects. The clinical significance is unknown.
• Thyroid hormones: Thyroid hormones also affect metabolic rate and fat oxidation. Additive effects are possible. Patients on thyroid replacement should be aware.
• Beta-blockers: Beta-blockers can suppress lipolysis by blocking beta-adrenergic signaling. They could theoretically reduce the fragment's effectiveness.

Contraindications

• Active cancer or recent cancer history — although the fragment does not raise IGF-1, any metabolic intervention should be discussed with an oncologist in the context of active malignancy
• Pregnancy and breastfeeding — no safety data available
• Children and adolescents — no pediatric data available; could theoretically interfere with normal growth-related fat metabolism
• Known allergy to HGH Fragment 176-191 or any component of the preparation
• Active eating disorders — use of fat-loss agents may exacerbate disordered eating behaviors

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Research

The Foundational Research: Monash University

The development of HGH Fragment 176-191 originated at Monash University in Melbourne, Australia, where researchers systematically analyzed different regions of the human growth hormone molecule to identify which structural domains were responsible for its various biological activities. The key research group was led by Frank Ng and Gary Borstein, whose work spanned from the mid-1990s through the mid-2000s.

Key Preclinical Studies

1. Lipolytic Activity in Obesity (Ng et al., 2000)

This landmark paper established the core finding: HGH Fragment 176-191 retains the fat-burning activity of full-length growth hormone while lacking its growth-promoting effects.

• Model: ob/ob mice (a genetic model of obesity) treated with HGH Fragment 176-191 subcutaneously for 18 days
• Key findings: The fragment produced significant reductions in body weight and fat mass, comparable to full-length hGH. It did not affect lean body mass, blood glucose levels, or insulin sensitivity. IGF-1 levels were unaffected.
• In vitro data: The fragment stimulated lipolysis in isolated human and rodent adipocytes, confirming direct action on fat cells.
• Significance: This was the first demonstration that a small peptide fragment could selectively isolate the lipolytic function of growth hormone.
• Citation: Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. "Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone." Horm Res. 2000;53(6):274-8.

2. Anti-Obesity Effects and Lipogenesis Inhibition (Wu et al., 2003)

This study expanded the characterization of the fragment's anti-obesity mechanism, demonstrating that it acts through both lipolysis stimulation and lipogenesis inhibition.

• Model: ob/ob mice treated chronically with the fragment
• Key findings: The fragment not only promoted fat breakdown but also inhibited the formation of new fat (lipogenesis). This dual mechanism — enhanced fat catabolism plus reduced fat anabolism — suggests a potentially more durable effect on body composition than lipolysis alone.
• Dose-response: The study established a dose-response relationship, with higher doses producing greater fat-mass reductions.
• No tachyphylaxis: The fragment maintained its effectiveness over the study period without evidence of diminishing response.
• Citation: Wu Z, Ng FM. "Antiobesity activity of a synthetic pentapeptide corresponding to hGH fragment 176-191." Int J Obes. 2003;27(Suppl 1):S38.

3. No Diabetogenic Action (Heffernan et al., 2001)

A critical safety study demonstrating that the fragment's fat-loss effects occur without the insulin resistance that limits clinical use of full-length HGH.

• Model: Obese Zucker rats (a model of insulin resistance and obesity)
• Key findings: The fragment reduced adiposity without affecting fasting glucose, fasting insulin, or glucose tolerance test results. In contrast, full-length hGH at equivalent lipolytic doses produced significant hyperglycemia and insulin resistance in the same model.
• Significance: This established the safety advantage of the fragment for metabolically compromised individuals — precisely the population most likely to need anti-obesity treatment.
• Citation: Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. "Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism." Am J Physiol Endocrinol Metab. 2000;279(3):E501-7.

4. Structure-Activity Relationships (Ng & Borstein, 2003)

This work characterized which amino acids within the 176-191 sequence are essential for lipolytic activity and led to the development of AOD-9604.

• Key findings: The addition of a tyrosine residue at the N-terminus (creating AOD-9604) enhanced the peptide's stability and potency. Specific amino acid substitutions within the sequence identified critical residues for receptor binding and lipolytic activation.
• Clinical development: This work provided the basis for advancing AOD-9604 into human clinical trials as a pharmaceutical-grade anti-obesity agent.
• Citation: Ng FM, Borstein J. "Human growth hormone fragment 176-191 and AOD-9604: review of anti-obesity effects." Horm Res. 2003;60(Suppl 3):91-93.

AOD-9604 Clinical Trials (Human Data)

AOD-9604, the pharmaceutical development of the HGH Fragment concept, represents the closest available human clinical evidence:

Phase 1 Studies

• Single ascending dose and multiple ascending dose studies in healthy volunteers
• Demonstrated safety and tolerability across a range of doses
• No significant adverse events, no effect on IGF-1, no effect on glucose tolerance
• Both subcutaneous and oral formulations were tested

Phase 2b Trial (Obesity)

• Design: Randomized, double-blind, placebo-controlled trial in approximately 300 obese adults
• Duration: 12 weeks of treatment
• Formulation: Oral AOD-9604
• Results: The 1 mg/day dose produced statistically significant weight loss compared to placebo (approximately 2.6 kg difference). Higher doses did not produce proportionally greater weight loss, suggesting a ceiling effect at the doses tested.
• Safety: Well tolerated; adverse events similar to placebo; no metabolic safety signals
• Outcome: Despite statistical significance, the magnitude of weight loss was considered insufficient for regulatory approval as a stand-alone obesity drug. The development program was not advanced to Phase 3.
• Citation: Stier H, Vos E, Kenley D. "Safety and tolerability of the hexadecapeptide AOD9604 in humans." Growth Horm IGF Res. 2011;21(Suppl 1):S56.

AOD-9604 in Osteoarthritis

• Subsequent research investigated AOD-9604 for osteoarthritis and cartilage repair
• Preclinical studies showed chondroprotective effects — protecting cartilage from degradation and possibly stimulating repair
• Clinical trials for intra-articular injection in knee osteoarthritis have been conducted
• The Australian Therapeutic Goods Administration (TGA) granted AOD-9604 Generally Recognized as Safe (GRAS) status for use as a food additive in 2011
• Citation: Kwon DR, Park GY. "Effect of intra-articular injection of AOD9604 with hyaluronic acid in rabbit osteoarthritis model." Cartilage. 2012;3(Suppl):155S.

Limitations of the Research

Several important caveats apply to the HGH Fragment 176-191 evidence base:

• Primarily animal data: The core evidence for the fragment itself is from rodent models. Animal obesity models (ob/ob mice, Zucker rats) do not perfectly replicate human obesity biology.
• Single research group: Most foundational research comes from the Ng/Borstein laboratory at Monash University. Independent replication by other groups has been limited.
• AOD-9604 is not identical to Fragment 176-191: The human clinical data is from AOD-9604, which has an additional tyrosine residue. While the two are pharmacologically similar, they are not identical molecules. Extrapolating AOD-9604 data to the unmodified fragment involves assumptions.
• Oral vs. injectable: The human clinical trials used oral AOD-9604. HGH Fragment 176-191 is typically used as a subcutaneous injection. Different routes may yield different pharmacokinetics and efficacy.
• No Phase 3 data: Neither compound has completed a Phase 3 clinical trial. The level of evidence does not meet regulatory standards for drug approval.
• Modest human results: The AOD-9604 Phase 2b results, while statistically significant, showed modest absolute weight loss (~2.6 kg over placebo in 12 weeks). This is less impressive than modern anti-obesity drugs (e.g., GLP-1 receptor agonists, which produce 10–20% body weight loss).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Regulatory Status

FDA Status

Important Legal Distinction: HGH Fragment vs. Full HGH

Full-length human growth hormone (somatropin) occupies a unique legal position in the United States. Under the 1990 Anabolic Steroids Control Act and subsequent amendments, the distribution of HGH for non-approved purposes is a federal crime (21 U.S.C. § 333(e)). This makes HGH one of the few non-scheduled substances with specific criminal penalties for off-label distribution.

HGH Fragment 176-191 is NOT subject to these same restrictions. It is a peptide fragment, not full-length HGH, and is not covered by the HGH-specific provisions of federal law. It occupies the same regulatory space as other research peptides — not approved, not controlled, available through research suppliers.

AOD-9604 Regulatory Status

WADA Prohibited Status

Both HGH Fragment 176-191 and AOD-9604 are prohibited by the World Anti-Doping Agency (WADA).

• Classification: Listed under Section S0 (Non-Approved Substances) — the category covering "any pharmacological substance which is not addressed by any of the subsequent sections of the list and with no current approval by any governmental regulatory health authority for human therapeutic use."
• Additionally: Growth hormone fragments may also be captured under Section S2 (Peptide Hormones, Growth Factors, Related Substances), which prohibits growth hormone and its fragments.
• Testing: WADA-accredited laboratories have developed detection methods for growth hormone fragments in biological samples. Athletes subject to anti-doping testing should avoid these compounds entirely.
• Sanctions: Standard anti-doping sanctions apply. No TUE (Therapeutic Use Exemption) pathway exists because the compounds have no approved therapeutic use.

Legal Considerations for Consumers

For individuals considering HGH Fragment 176-191:

• Possession: Not illegal in most jurisdictions (it is not a controlled substance). However, laws vary by country and state.
• Purchase: Available from research chemical suppliers. Products are typically labeled "for research purposes only." Purchasing for personal use exists in a legal gray area.
• Quality regulation: Research chemical products are not subject to pharmaceutical-grade manufacturing standards. Purity, potency, and sterility are not guaranteed by regulatory oversight.
• Medical supervision: Any use should ideally occur under the supervision of a qualified healthcare provider who can monitor for adverse effects and ensure appropriate dosing.
• Competitive athletes: Use is prohibited under WADA rules and most professional and collegiate sports anti-doping policies. Detection tests exist and are in use.

Comparison: Regulatory Status of Related Compounds

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Cost

Typical Pricing

Cost Per Dose Breakdown

At the most commonly reported protocol (250 mcg twice daily = 500 mcg/day):

Insurance Coverage

HGH Fragment 176-191 is not covered by any insurance plan. Because it has no FDA-approved indication, it cannot be billed under any drug benefit, medical benefit, or prescription plan. All costs are out-of-pocket. This applies to all sources: research suppliers, compounding pharmacies, and clinic protocols.

Cost Comparison: HGH Fragment 176-191 vs. Alternatives

Value Assessment

When evaluating the cost-effectiveness of HGH Fragment 176-191, several factors should be considered:

• Compared to full HGH: The fragment costs approximately 5–20% of what full-length HGH costs. For individuals whose primary goal is fat loss (rather than muscle growth, anti-aging, or other HGH benefits), the fragment offers a significantly more affordable option with fewer side effects.
• Compared to GLP-1 agonists: Modern GLP-1 receptor agonists (semaglutide, tirzepatide) are far more expensive but also produce far greater weight loss (10–22% of body weight) with robust FDA approval and extensive safety data. For individuals with significant obesity, GLP-1 agonists offer better value per pound of weight lost.
• Compared to diet and exercise alone: The fragment adds $50–$250/month to a fat-loss program with an expected incremental benefit of 4–12 additional pounds of fat loss over a 2–3 month cycle. Whether this represents good value depends on individual financial circumstances and the importance placed on accelerated fat loss.
• Quality-price tradeoff: The cheapest peptide products carry higher risk of substandard quality, contamination, or inaccurate dosing. For a compound administered by injection, product quality is a safety consideration — not purely a value consideration.

Factors Affecting Cost

• Dosing protocol: Higher doses and more frequent dosing increase monthly cost proportionally.
• Cycle length: A 12-week cycle costs 50% more than an 8-week cycle.
• Provider fees: Clinics that prescribe the fragment may charge consultation fees ($100–$300) in addition to the peptide cost.
• Supplies: Factor in the cost of bacteriostatic water, insulin syringes, and alcohol swabs ($10–$20/month).
• Testing: Some users invest in periodic bloodwork or DEXA scans to track body composition changes ($100–$300 per test).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Questions & Answers

What is the difference between HGH Fragment 176-191 and AOD-9604?

Answer: HGH Fragment 176-191 and AOD-9604 are closely related but not identical. Both contain the amino acid sequence corresponding to positions 176–191 of human growth hormone. The key difference is that AOD-9604 has an additional tyrosine (Tyr) residue added at the N-terminus, making it a 17-amino-acid peptide versus the fragment's 16 amino acids. This modification was introduced by the Monash University research group to improve the peptide's stability and potency during pharmaceutical development. In terms of mechanism and effects, the two compounds are considered pharmacologically similar — both stimulate lipolysis and inhibit lipogenesis without affecting IGF-1 or blood glucose. AOD-9604 has more extensive clinical trial data because it was developed as a pharmaceutical candidate, while HGH Fragment 176-191 is available primarily as a research compound (Ng & Borstein, 2003).

How does HGH Fragment 176-191 compare to full-length HGH for fat loss?

Answer: Both stimulate lipolysis, but the scope of their effects is very different. Full-length HGH is a potent fat-loss agent but it also raises IGF-1 (promoting cell proliferation and organ growth), causes insulin resistance, produces fluid retention, and carries risks of carpal tunnel syndrome, joint pain, and acromegaly-like effects with long-term use. HGH Fragment 176-191 provides only the fat-loss component without these other effects. The trade-off is that the fragment lacks HGH's anabolic properties — it does not build muscle, strengthen bones, improve skin quality, or provide the other broad metabolic effects of full HGH. For individuals whose sole objective is targeted fat loss, the fragment offers a more favorable risk-benefit profile. For individuals seeking the broader spectrum of HGH effects, the fragment is insufficient (Ng et al., 2000).

Do I really need to inject HGH Fragment 176-191 in a fasted state?

Answer: Yes — this is considered essential, not optional. The fragment works by stimulating the lipolytic cascade, which involves cyclic AMP (cAMP) elevation and hormone-sensitive lipase (HSL) activation in adipocytes. Insulin directly suppresses this cascade by activating phosphodiesterase 3B, which degrades cAMP. Even modest insulin elevation from a small meal can largely negate the fragment's fat-burning effect. This is not a theoretical concern — it reflects established biochemistry of fat cell regulation. The consensus among practitioners is to inject at least 2 hours after the last meal and wait at least 30–60 minutes before eating afterward. The ideal windows are first thing in the morning (after overnight fast) and before bed (2–3 hours after dinner) (Ng et al., 2000).

Will HGH Fragment 176-191 cause the same side effects as HGH?

Answer: No. The critical distinction is that HGH Fragment 176-191 does not raise IGF-1 levels and does not affect glucose metabolism. The major side effects of full-length HGH — insulin resistance, fluid retention, carpal tunnel syndrome, joint pain, and the risk of organ enlargement — are mediated through IGF-1 elevation and full GH receptor activation, which the fragment does not produce. The fragment's side effect profile is substantially milder: injection site reactions, occasional headache, and lightheadedness. This is supported by both preclinical data and the AOD-9604 clinical trial safety database, which showed no significant adverse events in over 900 human subjects (Stier et al., 2011; Heffernan et al., 2001).

Can HGH Fragment 176-191 build muscle?

Answer: No. HGH Fragment 176-191 does not promote muscle hypertrophy, increase protein synthesis in muscle tissue, or enhance strength. It is exclusively a fat-metabolizing peptide. Full-length HGH's muscle-building effects are mediated primarily through IGF-1 stimulation and full GH receptor activation — pathways that the fragment does not engage. The fragment may indirectly improve body composition (making muscle more visible by reducing overlying fat), but it does not add muscle mass. Users seeking both fat loss and muscle growth would need to achieve the latter through other means (resistance training, nutrition, or other compounds).

How does HGH Fragment 176-191 compare to GLP-1 agonists like semaglutide?

Answer: These are fundamentally different approaches to body composition. GLP-1 receptor agonists (semaglutide/Wegovy, tirzepatide/Zepbound) are FDA-approved medications that produce dramatic weight loss (10–22% of body weight) primarily through appetite suppression — they make you eat less. HGH Fragment 176-191 is an unapproved research compound that modestly enhances fat oxidation — it makes your body burn slightly more stored fat during fasting. Key differences:

• Efficacy: GLP-1 agonists produce far greater weight loss (15–50+ lbs) vs. the fragment's estimated 4–12 lbs over a cycle
• Mechanism: Appetite suppression (GLP-1) vs. direct lipolysis stimulation (fragment)
• Evidence: Extensive Phase 3 data and FDA approval (GLP-1) vs. limited preclinical and Phase 2 data (fragment)
• Side effects: GI symptoms are common with GLP-1 agonists; the fragment has a very mild side effect profile
• Cost: GLP-1 agonists are much more expensive ($900–$1,600/month) vs. the fragment ($50–$250/month)
• Muscle loss: GLP-1 agonists can cause significant lean mass loss; the fragment appears to spare lean mass

For individuals with significant obesity (BMI >30), GLP-1 agonists are the more evidence-based choice. The fragment may be more appropriate for individuals closer to their target weight who want modest body composition refinement without appetite suppression.

Is HGH Fragment 176-191 the same as "HGH" sold online?

Answer: No. HGH Fragment 176-191 is a 16-amino-acid peptide fragment. Full-length HGH (somatropin) is a 191-amino-acid protein. They are completely different molecules with different effects. "HGH" products sold online (especially non-prescription products) are often:

• Amino acid supplements with no real HGH content
• "HGH releasers" (typically amino acids like arginine and ornithine) that may marginally increase GH secretion
• Homeopathic preparations with no active ingredient
• In some cases, counterfeit or mislabeled products

None of these are the same as pharmaceutical-grade somatropin or research-grade HGH Fragment 176-191. Genuine full-length HGH requires a prescription and is tightly regulated due to federal HGH distribution laws.

Can I take HGH Fragment 176-191 orally?

Answer: HGH Fragment 176-191 is not typically formulated for oral administration and would likely be degraded by digestive enzymes and stomach acid before significant absorption could occur. Unlike BPC-157 (which has unusual gastric acid stability), growth hormone fragments are not known to survive gastrointestinal transit intact. The related compound AOD-9604 was formulated with proprietary oral delivery technology for clinical trials, which may have enhanced its oral bioavailability through specialized formulation. Standard HGH Fragment 176-191 from research suppliers is intended for subcutaneous injection.

Will HGH Fragment 176-191 show up on a drug test?

Answer: On standard employment or forensic drug panels (which screen for drugs of abuse like amphetamines, opioids, cannabis, cocaine, and benzodiazepines) — no, the fragment will not be detected. However, in sports anti-doping testing (WADA, USADA, collegiate, professional sports), specific tests for growth hormone fragments have been developed and are in use. Athletes subject to anti-doping testing should consider any growth hormone fragment as a detectable prohibited substance.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Key Takeaways

Based on the available evidence:

• HGH Fragment 176-191 is a 16-amino-acid synthetic peptide corresponding to the C-terminal fat-metabolizing region of human growth hormone. It was developed by researchers at Monash University to isolate the lipolytic activity of HGH without its growth-promoting, insulin-disrupting, and other systemic effects.
• It stimulates lipolysis and inhibits lipogenesis — promoting the breakdown of stored fat and reducing the formation of new fat. Its mechanism of action involves activation of hormone-sensitive lipase in adipocytes through the beta-3 adrenergic/cAMP signaling pathway.
• It does NOT increase IGF-1, affect blood glucose, or promote tissue growth. This is its primary advantage over full-length HGH. The fragment lacks the structural domains required for full GH receptor activation, meaning it cannot drive the JAK2-STAT5/IGF-1 signaling cascade responsible for most of HGH's non-lipolytic effects.
• The evidence base is primarily preclinical. The foundational research comes from rodent models (ob/ob mice, Zucker rats) conducted by the Ng/Borstein group at Monash University. The closest human clinical data comes from trials of AOD-9604, the related compound, which showed statistically significant but modest weight loss in a Phase 2b trial.
• It is not FDA-approved for any indication. It is not a controlled substance but is classified as an unapproved research compound. AOD-9604 received GRAS status in Australia for food use but is not approved as a drug anywhere.
• Fasting is essential for the fragment to work. Insulin directly suppresses the lipolytic cascade the fragment stimulates. Administering in a fasted state (at least 2 hours after eating, 30–60 minutes before eating) is considered critical for efficacy.
• The safety profile appears favorable based on preclinical data and AOD-9604 clinical trials (900+ human subjects). Side effects are mild: injection site reactions, headache, lightheadedness. No serious adverse events have been reported. However, long-term human safety data beyond 12–24 weeks does not exist.
• Realistic expectations are modest. The fragment is a body composition refinement tool, not a dramatic weight-loss intervention. Estimated additional fat loss of 4–12 lbs over an 8–12 week cycle, when combined with diet and exercise, represents the reported range.
• Product quality varies significantly across research chemical suppliers. Purity, potency, and sterility are not guaranteed for unregulated research products. Source matters.
• Cost ranges from $50–$250/month depending on source and dosing protocol. It is significantly less expensive than full-length HGH but also produces narrower effects. Insurance does not cover it.

Who Might Consider HGH Fragment 176-191

Based on the available evidence and clinical practice patterns, HGH Fragment 176-191 may be worth discussing with a healthcare provider for individuals who:

• Have moderate excess body fat and are seeking a targeted lipolytic adjunct alongside an established diet and exercise program
• Have plateaued on fat loss despite consistent caloric deficit and exercise
• Want the fat-loss effects of growth hormone without the insulin resistance, fluid retention, and IGF-1 elevation of full HGH
• Have metabolic concerns (insulin resistance, pre-diabetes) that make full HGH contraindicated or risky
• Understand that the evidence is primarily preclinical and accept the associated uncertainty
• Have access to a knowledgeable provider who can guide dosing, timing, and monitoring

Who Should NOT Use HGH Fragment 176-191

• Individuals with active cancer or recent cancer history
• Pregnant or breastfeeding women
• Children or adolescents
• Competitive athletes subject to anti-doping testing
• Individuals with active eating disorders
• Individuals seeking significant weight loss (>20 lbs) — FDA-approved options like GLP-1 agonists are more appropriate
• Anyone unwilling or unable to maintain fasting protocols around injection times

Questions to Ask a Provider

• Based on my body composition goals, is HGH Fragment 176-191 a reasonable option, or would a different approach be more effective?
• How does this compare to other options for my specific situation (GLP-1 agonists, other peptides, lifestyle interventions)?
• What dosing protocol do you recommend, and what is the evidence basis?
• Where will the peptide be sourced, and what quality testing has been performed?
• What monitoring or bloodwork should I have during and after a cycle?
• Are there any interactions with my current medications or health conditions?
• What realistic results should I expect, and over what timeframe?

Sources & Further Reading

Foundational Research — HGH Fragment 176-191

• Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. "Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone." Horm Res. 2000;53(6):274-278.
• Wu Z, Ng FM. "Antiobesity activity of a synthetic pentapeptide corresponding to the C-terminal sequence of human growth hormone (hGH 177-191)." Int J Obes Relat Metab Disord. 2003;27(Suppl 1):S38.
• Ng FM, Borstein J. "Human growth hormone fragment and AOD-9604: review of metabolic effects." Horm Res. 2003;60(Suppl 3):91-93.
• Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. "Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism." Am J Physiol Endocrinol Metab. 2000;279(3):E501-507.

Mechanism of Action

• Ng et al. (2000) — Lipolysis stimulation and adipocyte-specific activity
• Wu & Ng (2003) — Lipogenesis inhibition and dual mechanism
• Heffernan et al. (2001) — No diabetogenic action; insulin and glucose unaffected
• Yip RG, Goodman HM. "Growth hormone and dexamethasone stimulate lipolysis and activate adenylyl cyclase in rat adipocytes by selectively shifting Gi alpha2 to lower density membrane fractions." Endocrinology. 1999;140(3):1219-1227.

AOD-9604 Clinical Trials

• Stier H, Vos E, Kenley D. "Safety and tolerability of the hexadecapeptide AOD9604 in humans." Growth Horm IGF Res. 2011;21(Suppl 1):S56.
• Ng & Borstein (2003) — Phase 2b obesity trial overview and clinical development
• Thompson G, Kenley D, Vos E. "AOD-9604: anti-obesity drug with no diabetogenic properties." Growth Horm IGF Res. 2007;17(Suppl A):S22-S23.

AOD-9604 in Osteoarthritis

• Kwon DR, Park GY. "Effect of intra-articular injection of AOD9604 with hyaluronic acid in rabbit osteoarthritis model." Cartilage. 2012;3(Suppl):155S.

Growth Hormone Physiology & Lipolysis

• Yip & Goodman (1999) — GH-stimulated lipolysis and adenylyl cyclase activation in adipocytes
• Moller N, Jorgensen JO. "Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects." Endocr Rev. 2009;30(2):152-177.
• Berryman DE, Glad CA, List EO, Johannsson G. "The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations." Nat Rev Endocrinol. 2013;9(6):346-356.
• Vijayakumar A, Novosyadlyy R, Wu Y, Yakar S, LeRoith D. "Biological effects of growth hormone on carbohydrate and lipid metabolism." Growth Horm IGF Res. 2010;20(1):1-7.

Insulin and Lipolysis Regulation

• Langin D. "Control of fatty acid and glycerol release in adipose tissue lipolysis." C R Biol. 2006;329(8):598-607.
• Duncan RE, Ahmadian M, Jaworski K, Sarkadi-Nagy E, Sul HS. "Regulation of lipolysis in adipocytes." Annu Rev Nutr. 2007;27:79-101.

Obesity Treatment Landscape (Context)

• Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." N Engl J Med. 2021;384(11):989-1002.
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide once weekly for the treatment of obesity." N Engl J Med. 2022;387(3):205-216.

Regulatory & Anti-Doping

• FDA: Bulk Drug Substances Used in Compounding
• WADA: Prohibited List (current year)
• Australian TGA: Therapeutic Goods Administration

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.